Fundraising Fox

/Companies

Phio Pharmaceuticals

NASDAQ: PHIO

Marlborough, US · Delaware corporation

Find your way into Phio Pharmaceuticals

Sign up to see every warm intro you have to Phio Pharmaceuticals

Paths you didn't know you had: your email and LinkedIn already hold routes to the Phio Pharmaceuticals team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with Google Already have an account? Log in

Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing INTASYL, a proprietary self-delivering siRNA gene silencing technology that makes immune cells more effective at killing cancer cells. Its immuno-oncology pipeline targets cutaneous squamous cell carcinoma (cSCC) and melanoma.

Biotech Deep Tech Healthtech

Founders & leadership

CM

Craig MelloCo-founder

GC

Geert Cauwenbergh

Geert Cauwenbergh President & Chief Executive Officer2012–2019Cauwenbergh is a pharmaceutical executive with 45+ years of industry experience, including founding and leading multiple biotech and pharmaceutical companies including Barrier Therapeutics and RXi Pharma (later Phio Pharmaceuticals), where he served as CEO from 2012 to 2019. He holds board positions at Phio Pharmaceuticals and other healthcare organizations, with expertise spanning dermatology, infectious disease, R&D, and general management.

GD

Gerrit Dispersyn

Gerrit Dispersyn President & Chief Executive Officer2019–2022Gerrit Dispersyn is an executive officer at Phio Pharmaceuticals with over 20 years of experience in biopharma and medtech operations, including roles in capital fundraising, clinical operations, product development, and M&A management. He holds dual US and Belgian citizenship and is multilingual.

LC

Lisa C. Carson

Lisa C. Carson Chief Financial OfficerLisa C. Carson is Chief Financial Officer of Phio Pharmaceuticals, a clinical-stage biopharmaceutical company developing INTASYL, a self-delivering siRNA gene silencing technology for immuno-oncology. She has held finance roles across life sciences, biotech, medical device, and Fortune 500 companies, and has guided early-stage life science companies through IPO processes.

CL

Curtis LockshinNamed on SEC filing

PD

Paul DormanNamed on SEC filing

KB

Keith BrownlieNamed on SEC filing

Board

CL

Curtis Lockshin, Ph.D.Board director

RJ

Robert J. BittermanBoard director

JE

Jonathan E. FreemanBoard director

PA

Patricia A. BradfordBoard director

RL

Robert L. FerraraBoard director

Reported raises · per SEC filings

Form D private placements

$32.3M disclosed across 16 rounds · 2017–2025

▶$1.4MraisedNov 2025 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Curtis Lockshin, Ph.D.Director
Patricia A. BradfordDirector
Robert J. BittermanDirector, Executive Officer
Lisa CarsonExecutive Officer
David H. DemingDirector
Jonathan FreemanDirector

Offering amount: $25.9M
Amount sold: $1.4M
Sales commissions: $1.1M
Placement agents: H.C. Wainwright & Co, LLC
First sale: Nov 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$232.1KraisedAug 2025 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Robert FerraraDirector
Jonathan FreemanDirector
Lisa CarsonExecutive Officer
Robert J. BittermanDirector, Executive Officer
David H. DemingDirector
Curtis Lockshin, Ph.D.Director
Patricia A. BradfordDirector

Offering amount: $5.1M
Amount sold: $232.1K
Sales commissions: $261.8K
First sale: Jul 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$152.5KraisedJan 2025 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Curtis Lockshin, Ph.D.Director
Patricia A. BradfordDirector
Robert FerraraDirector
Robert InfarinatoExecutive Officer, Promoter
Robert J. BittermanDirector, Executive Officer
Jonathan FreemanDirector

Offering amount: $3.7M
Amount sold: $152.5K
Sales commissions: $185.6K
Placement agents: H.C. Wainwright & Co, LLC
First sale: Jan 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$265.9KraisedJan 2025 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Robert J. BittermanDirector, Executive Officer
Robert InfarinatoExecutive Officer
Jonathan FreemanDirector
Patricia A. BradfordDirector
Robert FerraraDirector
Curtis Lockshin, Ph.D.Director

Offering amount: $6.4M
Amount sold: $265.9K
Sales commissions: $312.2K
Placement agents: H.C. Wainwright & Co, LLC
First sale: Jan 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$208.3KraisedJan 2025 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Robert FerraraDirector
Robert InfarinatoExecutive Officer, Promoter
Robert J. BittermanDirector, Executive Officer
Jonathan FreemanDirector
Patricia A. BradfordDirector
Curtis Lockshin, Ph.D.Director

Offering amount: $5M
Amount sold: $208.3K
Sales commissions: $253.4K
Placement agents: H.C. Wainwright & Co, LLC
First sale: Jan 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$30KraisedJan 2025 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Patricia A. BradfordDirector
Curtis Lockshin, Ph.D.Director
Robert InfarinatoExecutive Officer
Jonathan FreemanDirector
Robert FerraraDirector
Robert J. BittermanDirector, Executive Officer

Offering amount: $480K
Amount sold: $30K
Sales commissions: $60.8K
Placement agents: H.C. Wainwright & Co., LLC
First sale: Dec 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$54.6KraisedJan 2025 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Patricia A. BradfordDirector
Robert J. BittermanDirector, Executive Officer
Robert InfarinatoExecutive Officer
Robert FerraraDirector
Curtis Lockshin, Ph.D.Director
Jonathan FreemanDirector

Offering amount: $1.3M
Amount sold: $54.6K
Sales commissions: $138.9K
Placement agents: H.C. Wainwright & Co., LLC
First sale: Dec 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$136.3KraisedJul 2024 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Curtis A. Lockshin, Ph.D.Director
Robert J. BittermanDirector, Executive Officer
Jonathan E. FreemanDirector
Patricia A. BradfordDirector
Robert L. FerraraDirector

Offering amount: $6.4M
Amount sold: $136.3K
Sales commissions: $349.2K
Placement agents: H.C. Wainwright & Co., LLC
First sale: Jul 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.

RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

Companies working in the same space as Phio Pharmaceuticals.

In the news

Financial Information - Phio Pharmaceuticalsphiopharma.com · Apr 2023

Frequently asked questions

What does Phio Pharmaceuticals do?: Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing INTASYL, a proprietary self-delivering siRNA gene silencing technology that makes immune cells more effective at killing cancer cells. Its immuno-oncology pipeline targets cutaneous squamous cell carcinoma (cSCC) and melanoma.
Who founded Phio Pharmaceuticals?: Phio Pharmaceuticals was founded by Craig Mello.
How much funding has Phio Pharmaceuticals raised?: Phio Pharmaceuticals has disclosed $32.3M raised across 16 rounds.
Where is Phio Pharmaceuticals headquartered?: Phio Pharmaceuticals is headquartered in Marlborough, US.